Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC10A6 | Q3KNW5 | 3/20 | 0.69 |
| ▸ | SLC10A2 | Q12908 | 2/20 | 0.69 |
| ▸ | SLC10A1 | Q14973 | 2/20 | 0.69 |
| ▸ | GPR27 | Q9NS67 | 6/20 | 0.60 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.57 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | FLT1 | P17948 | 1/20 | 0.53 |
| ▸ | FLT4 | P35916 | 1/20 | 0.53 |
| ▸ | KDR | P35968 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.52 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6754585 | 0.91 | SLC10A6 (0.81) | SLC10A6SLC10A2SLC10A1GPR27KCNA5 | |
| SCHEMBL5115480 | 0.87 | SLC10A6 (0.61) | SLC10A6SLC10A2SLC10A1GPR27KCNA5 | |
| SCHEMBL5126770 | 0.86 | SLC10A6 (0.67) | SLC10A6SLC10A2SLC10A1GPR27KCNA5 | |
| SCHEMBL6760783 | 0.86 | SLC10A6 (0.74) | SLC10A6SLC10A2SLC10A1GPR27KCNA5 | |
| SCHEMBL491880 | 0.86 | SLC10A6 (0.60) | SLC10A6SLC10A2SLC10A1GPR27KCNA5 | |
| SCHEMBL491711 | 0.85 | SLC10A6 (0.72) | SLC10A6SLC10A2SLC10A1GPR27KCNA5 | |
| SCHEMBL491625 | 0.85 | SLC10A6 (0.72) | SLC10A6SLC10A2SLC10A1GPR27KCNA5 | |
| SCHEMBL7844614 | 0.85 | SLC10A6 (0.72) | SLC10A6SLC10A2SLC10A1GPR27KCNA5 | |
| SCHEMBL5115455 | 0.85 | SLC10A6 (0.88) | SLC10A6SLC10A2SLC10A1GPR27KCNA5 | |
| SCHEMBL492157 | 0.85 | SLC10A6 (0.72) | SLC10A6SLC10A2SLC10A1GPR27KCNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040167180-A1 | Methods for anti-tumor therapy | COMPASS PHARMACEUTICALS, LLC | 2004-08-26 | — | — | US | claimed |
| US-6716879-B2 | ADMINISTERING AN EFFECTIVE AMOUNT OF SULFONYLAMINO-SUBSTITUTED N-ARYL- OR HETEROACRYL OR ALKYL OR CYCLOALKYLCARBOXAMIDE DERIVATIVES OR SALTS, ESTERS, AMIDES OR PRODRUG TO TREAT TUMOR | COMPASS PHARMACEUTICALS, LLC | 2004-04-06 | — | — | US | claimed |
| EP-1317260-A2 | METHODS FOR TREATING TUMORS USING SULFONYL COMPOUNDS | Signature Bioscience, Inc. (US) | 2003-06-11 | — | — | EP | claimed |
| US-20020082243-A1 | Methods for anti-tumor therapy | PHOENIX ONCOLOGY, LLC | 2002-06-27 | — | — | US | claimed |
| WO-2002017897-A2 | METHODS FOR TREATING TUMORS USING SULFONYL COMPOUNDS | PRIMECYTE, INC. (US) | 2002-03-07 | — | — | WO | claimed |
| US-7351703-B2 | Sulfonylamino carboxylic acid N-arylamides as guanylate cyclase activators | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-04-01 | — | — | US | disclosed |
| EP-1095015-B1 | SULFONYLAMINO CARBOXYLIC ACID N-ARYLAMIDES AS GUANYLATE CYCLASE ACTIVATORS | AVENTIS PHARMA GMBH (DE) | 2005-06-01 | — | — | EP | disclosed |
| US-20050080073-A1 | Sulfonylaminocarboxiylic acid N-arylamides as guanylate cyclase activators | AVENTIS PHARMA DEUTSCHLAND GMBH | 2005-04-14 | — | — | US | disclosed |
| US-6809089-B2 | FOR THERAPY AND PROPHYLAXIS OF CARDIOVASCULAR DISORDERS SUCH AS HIGH BLOOD PRESSURE, ANGINA PECTORIS, CARDIAC INSUFFICIENCY, THROMBOSES OR ATHEROSCLEROSIS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-10-26 | — | — | US | disclosed |
| US-20030171352-A1 | Sulfonylaminocarboxylic acid N-arylamides as guanylate cyclase activators | AVENTIS PHARMA DEUTSCHLAND GMBH | 2003-09-11 | — | — | US | disclosed |
| EP-1317260-A2 | METHODS FOR TREATING TUMORS USING SULFONYL COMPOUNDS | Signature Bioscience, Inc. (US) | 2003-06-11 | — | — | EP | disclosed |
| US-6548547-B1 | Cardiovascular disorders; hypotensive agents, antiasthmatics, cognition activators | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-04-15 | — | — | US | disclosed |
| WO-2002017897-A2 | METHODS FOR TREATING TUMORS USING SULFONYL COMPOUNDS | PRIMECYTE, INC. (US) | 2002-03-07 | — | — | WO | disclosed |
| EP-1095015-A2 | SULFONYLAMINO CARBOXYLIC ACID N-ARYLAMIDES AS GUANYLATE CYCLASE ACTIVATORS | Aventis Pharma Deutschland GmbH (DE) | 2001-05-02 | — | — | EP | disclosed |
| WO-2000002850-A2 | SULFONYLAMINO CARBOXYLIC ACID N-ARYLAMIDES AS GUANYLATE CYCLASE ACTIVATORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082243-A1 | Methods for anti-tumor therapy | HCCS, PAICS, TP53 | SLC10A6 1719/4885SLC10A2 846/4885SLC10A1 941/4885 |
| US-20050080073-A1 | Sulfonylaminocarboxiylic acid N-arylamides as guanylate cyclase activators | GUCY1A1, GUCY1B1, GUCY1A2 | SLC10A6 2987/4885SLC10A2 1391/4885SLC10A1 1242/4885 |
| US-20030171352-A1 | Sulfonylaminocarboxylic acid N-arylamides as guanylate cyclase activators | GUCY1A1, GUCY1B1, GUCY1B2 | SLC10A6 3299/4885SLC10A2 1534/4885SLC10A1 1366/4885 |
| US-20040167180-A1 | Methods for anti-tumor therapy | HCCS, PAICS, TP53 | SLC10A6 1719/4885SLC10A2 846/4885SLC10A1 941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.